^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Bavencio (avelumab) (PD-L1 inhibitor) + pepinemab (VX15) (SEMA4D inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer
Published date:
04/05/2021
Excerpt:
This phase 1b/2, single arm study was designed to evaluate the safety, tolerability and efficacy of pepinemab in combination with avelumab in 62 patients with advanced NSCLC...ORR with the combination therapy was higher than previously reported for single agent avelumab in the PD-L1 negative / low population.
DOI:
10.1158/1078-0432.CCR-20-4792
